Spyre Therapeutics, Inc. SEC filings SYRE
Spyre Therapeutics, Inc. has 823 filings in SEC EDGAR's recent list, going back to Mar 24, 2015. Its latest annual report, Form ARS, was filed on Apr 10, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Mar 4, 2026 | — |
| EFFECT | Filing | Feb 27, 2026 | — |
| CORRESP | Letter to the SEC | Feb 25, 2026 | — |
| UPLOAD | Letter from the SEC | Feb 25, 2026 | — |
| UPLOAD | Letter from the SEC | Jun 2, 2025 | — |
| CORRESP | Letter to the SEC | May 21, 2025 | — |
| UPLOAD | Letter from the SEC | May 9, 2025 | — |
| EFFECT | Filing | Mar 13, 2025 | — |
| EFFECT | Filing | Mar 7, 2025 | — |
| CORRESP | Letter to the SEC | Mar 5, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 4, 2025 | — |
| EFFECT | Filing | Oct 2, 2024 | — |
| CORRESP | Letter to the SEC | Sep 30, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 26, 2024 | — |
| EFFECT | Filing | Sep 18, 2024 | — |
| CORRESP | Letter to the SEC | Sep 13, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 12, 2024 | — |
| EFFECT | Filing | Apr 29, 2024 | — |
| CORRESP | Letter to the SEC | Apr 25, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 25, 2024 | — |
| SEC STAFF LETTER | Filing | Apr 2, 2024 | — |
| EFFECT | Filing | Apr 1, 2024 | — |
| EFFECT | Filing | Apr 1, 2024 | — |
| CORRESP | Letter to the SEC | Mar 28, 2024 | — |
| CORRESP | Letter to the SEC | Mar 26, 2024 | — |
| CORRESP | Letter to the SEC | Mar 14, 2024 | — |
| UPLOAD | Letter from the SEC | Mar 8, 2024 | — |
| CORRESP | Letter to the SEC | Mar 1, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 16, 2024 | — |
| CORRESP | Letter to the SEC | Feb 2, 2024 | — |
| SEC STAFF LETTER | Filing | Jan 19, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 18, 2024 | — |
| D | Filing | Dec 27, 2023 | — |
| EFFECT | Filing | Nov 20, 2023 | — |
| CORRESP | Letter to the SEC | Nov 17, 2023 | — |
| CORRESP | Letter to the SEC | Nov 15, 2023 | — |
| CORRESP | Letter to the SEC | Oct 26, 2023 | — |
| UPLOAD | Letter from the SEC | Oct 24, 2023 | — |
| UPLOAD | Letter from the SEC | Oct 20, 2023 | — |
| PRER14A | Filing | Oct 10, 2023 | — |
| CORRESP | Letter to the SEC | Oct 6, 2023 | — |
| CORRESP | Letter to the SEC | Oct 6, 2023 | — |
| UPLOAD | Letter from the SEC | Sep 29, 2023 | — |
| CORRESP | Letter to the SEC | Sep 8, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 28, 2023 | — |
| D | Filing | Jul 6, 2023 | — |
| EFFECT | Filing | Jun 8, 2021 | — |
| CORRESP | Letter to the SEC | Jun 4, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 4, 2021 | — |
| EFFECT | Filing | Jul 14, 2020 | — |
| CORRESP | Letter to the SEC | Jul 10, 2020 | — |
| UPLOAD | Letter from the SEC | Jul 10, 2020 | — |
| CT ORDER | Filing | Mar 19, 2019 | — |
| EFFECT | Filing | Feb 13, 2019 | — |
| CORRESP | Letter to the SEC | Feb 11, 2019 | — |
| UPLOAD | Letter from the SEC | Feb 4, 2019 | — |
| CT ORDER | Filing | Mar 20, 2018 | — |
| CT ORDER | Filing | Nov 21, 2017 | — |
| EFFECT | Filing | May 30, 2017 | — |
| CORRESP | Letter to the SEC | May 25, 2017 | — |
| UPLOAD | Letter from the SEC | May 22, 2017 | — |
| CORRESP | Letter to the SEC | May 18, 2017 | — |
| CORRESP | Letter to the SEC | May 12, 2017 | — |
| UPLOAD | Letter from the SEC | May 10, 2017 | — |
| CT ORDER | Filing | Apr 25, 2017 | — |
| CT ORDER | Filing | Dec 6, 2016 | — |
| CERTNAS | Auto-generated paper document | Jun 28, 2016 | — |
| CERTNAS | Auto-generated paper document | Jun 13, 2016 | — |
| EFFECT | Filing | Apr 7, 2016 | — |
| CT ORDER | Filing | Apr 7, 2016 | — |
| EFFECT | Filing | Apr 6, 2016 | — |
| CORRESP | Letter to the SEC | Apr 4, 2016 | — |
| CORRESP | Letter to the SEC | Apr 4, 2016 | — |
| CERTNAS | Auto-generated paper document | Mar 31, 2016 | — |
| UPLOAD | Letter from the SEC | Mar 30, 2016 | — |
| CORRESP | Letter to the SEC | Mar 29, 2016 | — |
| 8-A12B | Filing | Mar 28, 2016 | — |
| CORRESP | Letter to the SEC | Mar 24, 2016 | — |
| UPLOAD | Letter from the SEC | Mar 24, 2016 | — |
| CORRESP | Letter to the SEC | Mar 22, 2016 | — |
| CORRESP | Letter to the SEC | Jun 24, 2015 | — |
| UPLOAD | Letter from the SEC | Jun 3, 2015 | — |
| DRS | Filing | May 6, 2015 | — |
| D | Filing | Mar 24, 2015 | — |
Showing 84 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SYRE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1636282
- Former names
- Aeglea BioTherapeutics, Inc. (until Nov 24, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.